» Articles » PMID: 9838071

Injection of the Protein Kinase C Inhibitor Ro31-8220 into the Nucleus Accumbens Attenuates the Acute Response to Amphetamine: Tissue and Behavioral Studies

Overview
Journal Brain Res
Specialty Neurology
Date 1998 Dec 5
PMID 9838071
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of amphetamine to produce heightened locomotor activity is thought to be due to its ability to enhance dopamine release from mesolimbic dopamine neurons. The mechanism by which amphetamine increases dopamine release is not well understood, but is thought to involve exchange diffusion with synaptosomal dopamine through the dopamine transporter. We recently reported that amphetamine-mediated dopamine release in the striatum is also dependent on protein kinase C activity. In the current study, we investigated the role of protein kinase C activity in the acute neurochemical and behavioral response to amphetamine in the nucleus accumbens. Consistent with previous results in the striatum, amphetamine-stimulated dopamine release from nucleus accumbens tissue was inhibited by the specific protein kinase C inhibitor Ro31-8220, but not by the relatively inactive analog bisindoylmaleimide V. In addition, the effects of protein kinase C activity on the acute behavioral response to amphetamine was examined by injecting Ro31-8220 into the nucleus accumbens 15 min prior to intra-accumbens amphetamine. Pretreatment with Ro31-8220 attenuated the motor-stimulant effects of intra-accumbens amphetamine relative to control subjects pretreated with vehicle. Bisindoylmaleimide V did not significantly inhibit the motor-stimulant effects of intra-accumbens amphetamine. These results suggest that the action of amphetamine in the nucleus accumbens in increasing dopamine release and locomotor activity is dependent on protein kinase C activity.

Citing Articles

PKC inhibition decreases amphetamine-maintained responding under a progressive-ratio schedule of reinforcement.

Altshuler R, Mac R, Gnegy M, Jutkiewicz E Exp Clin Psychopharmacol. 2020; 29(6):567-572.

PMID: 32940488 PMC: 8611615. DOI: 10.1037/pha0000425.


The protein kinase Cβ-selective inhibitor, enzastaurin, attenuates amphetamine-stimulated locomotor activity and self-administration behaviors in rats.

Altshuler R, Carpenter C, Franke T, Gnegy M, Jutkiewicz E Psychopharmacology (Berl). 2019; 236(11):3231-3242.

PMID: 31134292 PMC: 6832797. DOI: 10.1007/s00213-019-05278-0.


Phosphorylation of the Amino Terminus of the Dopamine Transporter: Regulatory Mechanisms and Implications for Amphetamine Action.

Karam C, Javitch J Adv Pharmacol. 2018; 82:205-234.

PMID: 29413521 PMC: 6341980. DOI: 10.1016/bs.apha.2017.09.002.


Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects.

Carpenter C, Zestos A, Altshuler R, Sorenson R, Guptaroy B, Showalter H Neuropsychopharmacology. 2017; 42(10):1940-1949.

PMID: 28492278 PMC: 5561350. DOI: 10.1038/npp.2017.95.


Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.

Carpenter C, Sorenson R, Jin Y, Klossowski S, Cierpicki T, Gnegy M Bioorg Med Chem. 2016; 24(21):5495-5504.

PMID: 27647375 PMC: 5696786. DOI: 10.1016/j.bmc.2016.09.002.